Monopar Therapeutics 3Q 2026: EPS ($0.72) — 10-Q Summary
Monopar Therapeutics reported a widened net loss for 3Q 2026, with increased R&D and administrative expenses. The company began NDA submission for ALXN1840 and expects funds to last until March 2028. Net loss was $6.2M, with diluted EPS at -$0.72.
How this was made

The 30-second read
Why it matters
The widened loss and EPS decline suggest short‑term downside, but the ongoing NDA submission and funded runway provide a longer‑term catalyst.
Market read
Primary micro‑cap earnings release with modest scale; relevant mainly to biotech and specialty pharma traders.
What to watch
The company still has funding secured through 2028, which may cushion short‑term volatility.
Background
Monopar Therapeutics (NASDAQ: MNPR) filed its Q3 2026 10‑Q, summarizing financial and operational highlights.
Ticker impact
Monopar Therapeutics reported a widened net loss and lower EPS in its Q3 2026 10‑Q filing.
downward pressure as investors price in the larger loss and higher expenses
Earnings miss and higher R&D spend suggest short‑term downside risk despite ongoing NDA submission.
Market effects
Highlights continued cash burn in the radiopharmaceutical biotech sector.
Limited to U.S. biotech investors; no broader regional effect.
Minimal; the news is company‑specific.
Counterpoint
If the NDA rollout for ALXN1840 succeeds, the long‑term upside could outweigh the near‑term loss.
Key entities
- companyMonopar Therapeutics
Biotech firm developing radiopharmaceuticals, ticker MNPR.
